-
2018
Year - Service
-
Soneas
Client
Corbett Keeling has advised SONEAS and its shareholders on its sale to UQUIFA, the Vivimed Group's API business. Soneas broadens Uquifa's offering in the CDMO sector with new development capabilities and an enhance project pipeline.
About Soneas Soneas, established in 1996, with a team strength of 144 people, is a Budapest headquartered firm with business verticals focused on research, development, and custom manufacturing, targeted at the innovator pharma and fine chemical sectors.
About Uquifa Uquifa has three FDA inspected manufacturing sites across Spain and Mexico and caters to the generic and ethical API segments of the global pharma market. It has had a trusted franchise across regulated markets for 80 years.
Testimonials
"Uquifa believes the acquisition of Soneas will allow it to expand faster into the CDMO sector (40% of Uquifa sales) where it already has an important presence in the geographies of USA, Europe and Japan. To build on the cost-effective development capabilities with aggressive timelines and, to deliver effective results for the combined customer base, will be a key objective for Uquifa."
Saurabh Gurnurkar, Executive Director, Uquifa